Table 1 Genetic association analysis was performed for beryllium-exposed individuals without disease (BeEx), beryllium sensitization (BeS), or diagnosed chronic beryllium disease (CBD) using a candidate gene approach

BeS

BeEx

0.730

(0.331–1.278), p = 0.443

1.191

(0.776–1.780), p = 0.478

1.020

(0.663–1.629), p = 1.000

1.214

(0.889–1.670), p = 0.258

1.037

(0.690–1.608), p = 0.952

0.950

(0.619–1.413), p = 0.887

1.165

(0.649–1.948), p = 0.681

1.271

(0.941–1.719), p = 0.134

1.354

(1.002–1.829), p = 0.055*

1.126

(0.830–1.528), p = 0.490

CBD

BeEx

0.969

(0.495–1.704), p = 1.000

1.179

(0.765–1.767), p = 0.517

0.912

(0.600–1.431), p = 0.767

0.770

(0.566–1.048), p = 0.113

1.143

(0.757–1.790), p = 0.615

0.877

(0.567–1.310), p = 0.603

1.165

(0.649–1.948), p = 0.681

0.858

(0.627–1.166), p = 0.372

0.952

(0.696–1.293), p = 0.815

1.203

(0.883–1.640), p = 0.272

CBD

BeS

1.3456

(0.543–3.513), p = 0.675

0.987

(0.696–1.696), p = 1.000

0.899

(0.498–1.612), p = 0.834

0.648

(0.425–0.977), p = 0.044

1.103

(0.622–1.967), p = 0.850

0.922

(0.524–1.615), p = 0.886

1.000

(0.455–2.200), p = 1.000

0.712

(0.482–1.044), p = 0.075

0.736

(0.499–1.079), p = 0.112

1.072

(0.700–1.645), p = 0.836

CBD + 

BeS

BeEx

0.837

(0.5056–1.37), p = 0.561

1.184

(0.866–1.599), p = 0.325

0.964 (0.702-

1.343), p = 0.890

0.965

(0.769–1.212), p = 0.800

1.089

(0.802–1.500), p = 0.654

0.913

(0.668–1.229), p = 0.607

1.167

(0.764–1.730), p = 0.518

1.048

(0.838–1.308), p = 0.722

1.137

(0.910–1.42), p = 0.275

1.164

(0.928–1.461), p = 0.208

CBD

BeEx + BeS

0.991

(0.509–1.736), p = 1.000

1.157

(0.755–1.734), p = 0.564

0.912

(0.603–1.425), p = 0.760

0.759

(0.560–1.030), p = 0.089

1.141

(0.755–1.786), p = 0.623

0.8789

(0.568–1.315), p = 0.616

1.150

(0.640–1.924), p = 0.717

0.842

(0.618–1.140), p = 0.300

0.927

(0.681–1.255), p = 0.680

1.191

(0.874–1.623), p = 0.300